Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01441414 · ClinicalTrials.gov registry record · Phase 2
PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT01441414 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 18 participants.
The verdict
NCT01441414, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
To evaluate the combination of PF-04856884 (CVX-060) in combination with Axitinib (AG-013736) in patients that have received one prior systemic regimen for metastatic renal cell carcinoma (mRCC) vs. axitinib alone.
Interventions
- DRUG Axitinib (AG-013736)
- BIOLOGICAL PF-04856884
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2011-11-21 |
| Est. Completion | 2014-03-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01441414
The ClinicalTrials.gov registry entry for NCT01441414 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Axitinib (AG-013736) is the first listed.
NCT01441414 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01441414 about?
NCT01441414 is a clinical study titled "PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma". To evaluate the combination of PF-04856884 (CVX-060) in combination with Axitinib (AG-013736) in patients that have received one prior systemic regimen for metastatic renal cell carcinoma (mRCC) vs. axitinib alone.
What is the current status of trial NCT01441414?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2011-11-21. Estimated completion is 2014-03-27.
What interventions are being tested in trial NCT01441414?
The interventions under investigation include: Axitinib (AG-013736) (DRUG), PF-04856884 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01441414?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.